<DOC>
	<DOCNO>NCT03068312</DOCNO>
	<brief_summary>This study evaluate efficacy ivacaftor treatment subject CF 6 year age old 3849 + 10KB C→T D1152H CFTR mutation .</brief_summary>
	<brief_title>A Study Evaluate Efficacy Ivacaftor Subjects With Cystic Fibrosis Who Have 3849 + 10KB C→T D1152H CFTR Mutation</brief_title>
	<detailed_description />
	<mesh_term>Fibrosis</mesh_term>
	<mesh_term>Cystic Fibrosis</mesh_term>
	<criteria>Confirmed diagnosis CF base protocolspecified clinical feature least one following : increased sweat chloride level , identification 2 CF cause mutation , demonstration abnormal nasal epithelial ion transport . A 3849 + 10KB C→T D1152H mutation least 1 CFTR allele . FEV1 ≥40 % predict ≤105 % predict screening . A G551D , G1244E , G1349D , G178R , G551S , S1251N , S1255P , S549N , S549R , R117H mutation . History illness clinical condition , opinion investigator , might confound result study pose additional risk administer study drug subject . Ongoing prior participation investigational drug study within 30 day Screening Visit . Protocolspecified abnormal laboratory value Screening Visit For subject &lt; 18 year age Screening Visit , evidence cataract/lens opacity determine clinically significant ophthalmologist optometrist ophthalmologic examination ( OE ) Screening Visit . Use moderate strong inducer inhibitor cytochrome P450 ( CYP ) 3A , include consumption certain herbal medication certain fruit fruit juice , within 14 day Day 1 . Pregnant , breastfeeding , plan become pregnant study . Sexually active subject reproductive potential must willing use appropriate contraception .</criteria>
	<gender>All</gender>
	<minimum_age>6 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2017</verification_date>
</DOC>